Brokerages Set NewAmsterdam Pharma (NASDAQ:NAMS) PT at $43.33
Shares of NewAmsterdam Pharma (NASDAQ:NAMS – Get Free Report) have been given an average rating of “Buy” by the six analysts that are currently covering the stock, MarketBeat Ratings reports. Six research analysts have rated the stock with a buy rating. The average 1-year price target among analysts that have covered the stock in the […]
Shares of NewAmsterdam Pharma (NASDAQ:NAMS – Get Free Report) have been given an average rating of “Buy” by the six analysts that are currently covering the stock, MarketBeat Ratings reports. Six research analysts have rated the stock with a buy rating. The average 1-year price target among analysts that have covered the stock in the […]
